Robert A. Freedman

206-389-4524
rfreedman@fenwick.com
Partner
Corporate

Robert A.
Freedman

Robert A.
Freedman

Robert A.
Freedman

Partner
Corporate

Leveraging more than 25 years of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in going public transactions, including IPOs, SPACs, reverse mergers, direct listings, as well as in follow-on offerings and private placements of equity and debt securities. Rob also advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including corporate governance, public company reporting, and stock exchange rules and requirements.

Clients praise Rob's "very good technical skill set, terrific work and very up-to-date advice on complex capital markets transactions."

Chambers USA, Client Quote

2020 Edition

Rob helps clients raise capital, navigate risk, and tell a story through filings and disclosures over the long term. For example, he represented Loxo Oncology in its IPO, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public and private offerings of equity and debt. Rob is committed to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA and Chambers Global, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019 program.

Read more

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • Augmedix
  • Castlight Health
  • Corium International
  • Cowen and Company
  • Day One Biopharmaceuticals
  • Dermira
  • Dexcom
  • DICE Therapeutics
  • Elevation Oncology
  • Goldman Sachs
  • Graybug Vision
  • Kalvista
  • Loxo Oncology
  • Morphic Holding
  • Neoleukin Therapeutics
  • Obalon Therapeutics
  • Passage Bio
  • Piper Jaffray
  • Sema4
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics
  • Sutro Biopharma
  • Upwork

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • Augmedix
  • Castlight Health
  • Corium International
  • Cowen and Company
  • Day One Biopharmaceuticals
  • Dermira
  • Dexcom
  • DICE Therapeutics
  • Elevation Oncology
  • Goldman Sachs
  • Graybug Vision
  • Kalvista
  • Loxo Oncology
  • Morphic Holding
  • Neoleukin Therapeutics
  • Obalon Therapeutics
  • Passage Bio
  • Piper Jaffray
  • Sema4
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics
  • Sutro Biopharma
  • Upwork

  • Loxo Oncology in its $8B acquisition by Lilly
  • Augmedix in its private placement and reverse merger with Malo Holdings Corp.
  • Castlight Health in its acquisition of Jiff
  • Corium in its $504M acquisition by Gurnet Point Capital
  • KalVista Pharmaceuticals in its share purchase agreement with Carbylan Therapeutics
  • Neoleukin Therapeutics in its reverse merger with Aquinox Pharmaceuticals
  • OncoGenex Pharmaceuticals in its merger with Achieve Life Science
  • Pixium Vision in its business combination with Second Sight Medical Products
  • Sema4 in its combination agreement with CM Life Sciences SPAC
  • Data Domain in its $2.4B acquisition by EMC
  • Cisco Systems in its $3.2B acquisition of WebEx Communications
  • Macromedia in its $3.4B merger with Adobe
  • Zappos.com in its $847M acquisition by Amazon.com

  • Loxo Oncology in its $8B acquisition by Lilly
  • Augmedix in its private placement and reverse merger with Malo Holdings Corp.
  • Castlight Health in its acquisition of Jiff
  • Corium in its $504M acquisition by Gurnet Point Capital
  • KalVista Pharmaceuticals in its share purchase agreement with Carbylan Therapeutics
  • Neoleukin Therapeutics in its reverse merger with Aquinox Pharmaceuticals
  • OncoGenex Pharmaceuticals in its merger with Achieve Life Science
  • Pixium Vision in its business combination with Second Sight Medical Products
  • Sema4 in its combination agreement with CM Life Sciences SPAC
  • Data Domain in its $2.4B acquisition by EMC
  • Cisco Systems in its $3.2B acquisition of WebEx Communications
  • Macromedia in its $3.4B merger with Adobe
  • Zappos.com in its $847M acquisition by Amazon.com

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • BioPharmX
  • Boku
  • Cascadian Therapeutics
  • Castlight Health
  • Corium
  • Concur Technologies
  • Data Domain
  • Dexcom
  • Handspring
  • KalVista
  • Keynetics
  • Loxo Oncology
  • Macromedia
  • Marvell Technology Group
  • Morphic Therapeutic
  • Neoleukin Therapeutics
  • Nurix Therapeutics
  • Sema4
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics
  • Sutro Biopharma
  • Upwork
  • Veracyte

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • BioPharmX
  • Boku
  • Cascadian Therapeutics
  • Castlight Health
  • Corium
  • Concur Technologies
  • Data Domain
  • Dexcom
  • Handspring
  • KalVista
  • Keynetics
  • Loxo Oncology
  • Macromedia
  • Marvell Technology Group
  • Morphic Therapeutic
  • Neoleukin Therapeutics
  • Nurix Therapeutics
  • Sema4
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics
  • Sutro Biopharma
  • Upwork
  • Veracyte

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
Chambers Global and Chambers USA

2020 - 2022

Ranked Rob as a top capital markets lawyer.

U.S. News - Best Lawyers

2019 - 2021

Named Rob "Lawyer of the Year" in corporate law (2020), and recognized him among “The Best Lawyers in America” for his work in corporate law, and securities and capital markets law (2019 – 2021).

The Legal 500

2022

Highlighted among the United States’ leading lawyers for capital markets and healthcare: life sciences work.

LMG Life Sciences

2019

Recognized Rob as a Star.

  • Chambers USA recognized Rob as a leading lawyer in capital markets in California (2022)
  • Chambers USA ranked Rob as a top capital markets lawyer nationwide (2019 – 2022)
  • US News recognized Rob for his excellence in securities and capital markets law and corporate law (2019)
  • The Legal 500 recognized Rob for his capital markets practice (2016 – 2020)

Recognition
Chambers Global and Chambers USA

2020 - 2022

Ranked Rob as a top capital markets lawyer.

U.S. News - Best Lawyers

2019 - 2021

Named Rob "Lawyer of the Year" in corporate law (2020), and recognized him among “The Best Lawyers in America” for his work in corporate law, and securities and capital markets law (2019 – 2021).

The Legal 500

2022

Highlighted among the United States’ leading lawyers for capital markets and healthcare: life sciences work.

LMG Life Sciences

2019

Recognized Rob as a Star.

Login

Don’t have an account yet?

Register